Author

J. H. Grosset

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

D. Almeida· 1 shared E. Nuermberger· 1 shared E. Nuermburger· 1 shared J. Lee· 1 shared N. C. Ammerman· 1 shared P. J. Converse· 1 shared R. Chaisson· 1 shared R. Tasneen· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

D. Almeida

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis

V. Saini, N. C. Ammerman, Y. S. Chang, R. Tasneen, R. Chaisson, S. K. Jain, E. Nuermburger, J. H. Grosset

This study tests a new TB treatment regimen combining high-dose rifapentine and clofazimine in mouse models, finding it more effective than either drug alone in shortening treatment duration.

bioRxiv · Feb 21, 2019Microbiology

High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease

T. F. Omansen, D. Almeida, P. J. Converse, S.-Y. Li, J. Lee, Y. Stienstra, T. S. van der Werf, J. H. Grosset, E. Nuermberger

This study evaluates higher doses of rifamycins in a mouse model of Buruli ulcer, finding dose-dependent efficacy and potential for shorter treatment regimens.

bioRxiv · Aug 19, 2018Microbiology